Swedish natalizumab (Tysabri) multiple sclerosis surveillance study

Area of Science:

• Neurology
• Immunology
• Pharmacovigilance

Background:

• Natalalizumab is a treatment for multiple sclerosis (MS).
• Post-marketing surveillance is crucial for long-term safety and efficacy assessment.
• The Swedish MS registry provides a platform for nationwide patient monitoring.

Purpose of the Study:

• To monitor the safety and open-label efficacy of natalalizumab in a real-world setting.
• To assess clinical outcomes and adverse events in MS patients treated with natalalizumab.
• To evaluate the long-term safety profile, including rare but serious events like PML.

Main Methods:

• Implementation of a post-marketing surveillance program using the Swedish MS registry.
• Standardized follow-up including clinical assessments (EDSS, MSSS, SDMT, MSIS-29) and adverse event recording.
• Analysis of data from 1,115 patients, with a focus on 363 patients treated for ≥ 24 months.

Main Results:

• Significant improvements in clinical outcome parameters were observed for patients treated ≥ 24 months.
• A low dropout rate of 10% was recorded, primarily due to planned pregnancy.
• Serious adverse events were rare, with three cases of progressive multifocal leukoencephalopathy (PML) reported, none with prior immunosuppression.

Conclusions:

• Natalalizumab shows good general tolerability and sustained efficacy in patients with severe MS.
• The risk of progressive multifocal leukoencephalopathy (PML) remains a significant concern requiring vigilance.
• Long-term data supports the benefit-risk profile of natalalizumab in managing severe MS.